Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$201K Sell
63,955
-18,550
-22% -$58K ﹤0.01% 1011
2026
Q1
$241K Buy
82,505
+19,322
+31% +$55.2K ﹤0.01% 849
2025
Q4
$156K Sell
63,183
-8,507
-12% -$20.3K ﹤0.01% 945
2025
Q3
$160K Sell
71,690
-2,210
-3% -$5.06K ﹤0.01% 948
2025
Q2
$178K Buy
73,900
+37,847
+105% +$92.1K ﹤0.01% 896
2025
Q1
$84K Sell
36,053
-36,706
-50% -$73.4K ﹤0.01% 865
2024
Q4
$135K Buy
72,759
+5,512
+8% +$12.2K ﹤0.01% 816
2024
Q3
$164K Buy
67,247
+5,677
+9% +$12.7K ﹤0.01% 767
2024
Q2
$126K Sell
61,570
-10,625
-15% -$24.2K ﹤0.01% 715
2024
Q1
$179K Buy
72,195
+10,830
+18% +$28.2K ﹤0.01% 687
2023
Q4
$172K Buy
61,365
+25,724
+72% +$69.5K ﹤0.01% 634
2023
Q3
$92K Buy
35,641
+7,208
+25% +$20.8K ﹤0.01% 582
2023
Q2
$90.4K Buy
28,433
+13,255
+87% +$39K ﹤0.01% 586
2023
Q1
$42.8K Buy
15,178
+4,446
+41% +$11.6K ﹤0.01% 562
2022
Q4
$29.2K Sell
10,732
-123
-1% -$358 ﹤0.01% 509
2022
Q3
$31K Buy
+10,855
New +$30.8K ﹤0.01% 479
2022
Q2
Sell
-11,228
Closed -$36K 437
2022
Q1
$36K Buy
+11,228
New +$31.4K ﹤0.01% 468

Other funds holding ABEV

Ballentine Partners's ABEV Position: Q2 2026 in Review

Ballentine Partners reduced its Ambev (ABEV) stake by 22% in Q2 2026, selling an estimated $58K and leaving 63,955 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #1011.

Ballentine Partners first reported a position in ABEV in Q1 2022 and has held it in 17 quarters since. The position peaked at $241K in Q1 2026. 404 funds tracked by Wall St. Rank hold ABEV as of Q2 2026.

  • Ballentine Partners held 63,955 shares of Ambev worth $201K as of Q2 2026.
  • Ballentine Partners sold 18,550 Ambev shares in Q2 2026, an estimated $58K.
  • Ambev made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #1011 holding.
  • Ballentine Partners first reported a position in Ambev in Q1 2022 and has held it in 17 quarters since.
  • Ballentine Partners's Ambev position peaked at $241K in Q1 2026.
  • 404 funds tracked by Wall St. Rank held Ambev as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.